// App-Quantinova.ai

: Intensified Dosing of Gemtuzumab Ozogamicin Can be Safely Combined with Induction Chemotherapy in Children with Acute Myeloid Leukaemia (AML) and High Risk Myelodysplasia (MDS)

Researchers

Presenter

  • Brenda Gibson

Principal Investigators

  • Aimee E Houlton

  • Andre Baruchel

  • Guy Leverger

  • Owen P Smith

  • Anna Lawson

  • Keith Wheatley

  • Pamela R. Kearns

Medical Centers

  • Department of Hematology, Royal Hospital for Children, Glasgow, GBR

  • Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom

  • Department of Pediatric Hematology-Immunology, Robert Debre Hospital, Paris, France

  • Hopital Enfants Armand Trousseau, Paris, France

  • Pediatric Haematology, Our Lady's Children's Hospital, Dublin 12, Ireland

Locations

  • United Kingdom

  • France

  • Ireland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

  • Myelodysplastic Syndrome

Biomarkers

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Gemtuzumab ozogamicin

  • Daunorubicin

  • Mitoxantrone

  • fludarabine tablet

  • Cytarabine liposomal

  • Idarubicin Hydrochloride

Outcome

  • N/A

Study Design

  • Randomized

  • Multinational

  • Cohort

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved